10-Q 1 a05-14420_110q.htm 10-Q

 

U. S. SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

ý

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2005

 

PRESTIGE BRANDS HOLDINGS, INC.

 

Delaware

 

20-1297589

 

001-32433

(State of Incorporation)

 

(I.R.S. Employer Identification No.)

 

(Commission File Number)

 

PRESTIGE BRANDS INTERNATIONAL, LLC

 

Delaware

 

20-0941337

 

333-11715218-18

(State of Incorporation)

 

(I.R.S. Employer Identification No.)

 

(Commission File Number)

(Exact name of Registrants as specified in their charters)

 

90 North Broadway
Irvington, New York 10533

 

(914) 524-6810

(Address of Principal Executive Offices)

 

(Registrants’ telephone number, including area code)

 


 

This Quarterly Report on Form 10-Q is a combined quarterly report being filed separately by Prestige Brands Holdings, Inc. and Prestige Brands International LLC, both registrants.  Prestige Brands International, LLC, an indirect wholly owned subsidiary of Prestige Brands Holdings, Inc. is the indirect parent company of Prestige Brands, Inc., the issuer of our 9¼% senior subordinated notes due 2012, and the parent guarantor of such notes.  As the indirect holding company of Prestige Brands International, LLC, Prestige Brands Holdings, Inc. does not conduct ongoing business operations.  As a result, the financial information for Prestige Brands Holdings, Inc. and Prestige Brands International, LLC is identical for the purposes of the discussion of operating results in “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”  Unless otherwise indicated, we have presented information throughout this Form 10-Q for Prestige Brands Holdings, Inc. and its consolidated subsidiaries, including Prestige Brands International, LLC.  The information contained herein relating to each individual registrant is filed by such registrant on its own behalf.  Neither registrant makes any representation as to information relating to the other registrant.  Prestige Brands International, LLC meets the conditions set forth in general instructions (H)(1)(a) and (b) of Form 10-Q and is therefore filing this Form 10-Q with the reduced disclosure format.

 

Indicate by check mark whether the Registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrants were required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ý  No  o

 

Indicate by check mark whether the Registrants are accelerated filers (as defined in Exchange Act Rule 12b-2).  Yes  o  No  ý

 

As of August 5, 2005, Prestige Brands Holdings, Inc. had 50,053,423 shares of common stock outstanding.  As of such date, Prestige International Holdings, LLC, a wholly owned subsidiary of Prestige Brands Holdings, Inc., owned 100% of the uncertificated ownership interests of Prestige Brands International, LLC.

 

 



 

Prestige Brands Holdings, Inc.

Form 10-Q

Index

 

PART I.

FINANCIAL INFORMATION

 

 

 

 

Item 1.

Consolidated Financial Statements

 

 

Prestige Brands Holdings, Inc.

 

 

Consolidated Balance Sheets – June 30, 2005 and March 31, 2005 (unaudited)

 

 

Consolidated Statements of Operations – three months ended June 30, 2005 and 2004 (unaudited)

 

 

Consolidated Statement of Changes in Shareholders’ Equity and Comprehensive Income - three months ended June 30, 2005 (unaudited)

 

 

Consolidated Statements of Cash Flows - three months ended June 30, 2005 and 2004 (unaudited)

 

 

Notes to Unaudited Consolidated Financial Statements

 

 

 

 

 

Prestige Brands International, LLC

 

 

Consolidated Balance Sheets – June 30, 2005 (unaudited) and March 31, 2005

 

 

Consolidated Statements of Operations – three months ended June 30, 2005 and 2004 (unaudited)

 

 

Consolidated Statement of Changes in Members’ Equity and Comprehensive Income - three months ended June 30, 2005 (unaudited)

 

 

Consolidated Statements of Cash Flows - three months ended September 30, 2005 and 2004 (unaudited)

 

 

Notes to Unaudited Consolidated Financial Statements

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operation

 

 

 

 

Item 3.

Quantitative and Qualitative Disclosure About Market Risk

 

 

 

 

Item 4.

Controls and Procedures

 

 

 

 

PART II.

OTHER INFORMATION

 

 

 

 

Item 1.

Legal Proceedings

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

 

 

 

Item 3.

Defaults Upon Senior Securities

 

 

 

 

Item 4.

Submission of Matters to a Vote of Security Holders

 

 

 

 

Item 5.

Other Information

 

 

 

 

Item 6.

Exhibits

 

 

 

 

 

Signatures

 

 

1



 

Prestige Brands Holdings, Inc.

Consolidated Balance Sheets

(Unaudited)

 

(Dollars in thousands, except share data

 

 

 

June 30, 2005

 

March 31, 2005

 

Assets

 

 

 

 

 

Current assets

 

 

 

 

 

Cash

 

$

13,945

 

$

5,334

 

Accounts receivable

 

32,489

 

43,893

 

Inventories

 

27,946

 

21,580

 

Deferred income tax assets

 

6,965

 

5,699

 

Prepaid expenses and other current assets

 

4,039

 

3,152

 

Total current assets

 

85,384

 

79,658

 

 

 

 

 

 

 

Property and equipment

 

2,043

 

2,324

 

Goodwill

 

294,544

 

294,544

 

Intangible assets

 

606,465

 

608,613

 

Other long-term assets

 

14,344

 

15,996

 

 

 

 

 

 

 

Total Assets

 

$

1,002,780

 

$

1,001,135

 

 

 

 

 

 

 

Liabilities and Shareholders’ Equity

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable

 

$

18,626

 

$

21,705

 

Accrued liabilities

 

10,705

 

13,472

 

Current portion of long-term debt

 

3,730

 

3,730

 

Total current liabilities

 

33,061

 

38,907

 

 

 

 

 

 

 

Long-term debt

 

490,698

 

491,630

 

Deferred income tax liabilities

 

89,916

 

84,752

 

 

 

 

 

 

 

Total liabilities

 

613,675

 

615,289

 

 

 

 

 

 

 

Commitments and Contingencies – Note 7

 

 

 

 

 

 

 

 

 

 

 

Shareholders’ Equity

 

 

 

 

 

Preferred stock - $0.01 par value Authorized - 5,000,000 shares Issued and outstanding – None

 

 

 

Common stock - $.01 par value Authorized – 250,000,000 shares Issued and outstanding – 50,000,000 shares at June 30, 2005 and March 31, 2005

 

500

 

500

 

Additional paid-in capital

 

378,188

 

378,251

 

Treasury stock – 2,353 shares at cost

 

(4

)

(4

)

Accumulated other comprehensive income (loss)

 

(365

)

320

 

Retained earnings

 

10,786

 

6,779

 

Total shareholders’ equity

 

389,105

 

385,846

 

 

 

 

 

 

 

Total Liabilities and Shareholders’ Equity

 

$

1,002,780

 

$

1,001,135

 

 

See accompanying notes.

 

2



 

Prestige Brands Holdings, Inc.

Consolidated Statements of Operations

(Unaudited)

 

 

 

Three Months Ended June 30

 

(Dollars in thousands, except share data)

 

 

 

2005

 

2004

 

Revenues

 

 

 

 

 

Net sales

 

$

63,530

 

$

67,682

 

Other revenues

 

25

 

75

 

Total revenues

 

63,555

 

67,757

 

 

 

 

 

 

 

Costs of Sales

 

 

 

 

 

Costs of sales

 

28,339

 

36,123

 

Gross profit

 

35,216

 

31,634

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

Advertising and promotion

 

10,714

 

13,771

 

General and administrative

 

4,911

 

4,921

 

Depreciation

 

483

 

486

 

Amortization of intangible assets

 

2,148

 

1,803

 

Total operating expenses

 

18,256

 

20,981

 

 

 

 

 

 

 

Operating income

 

16,960

 

10,653

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

Interest income

 

81

 

28

 

Interest expense

 

(8,591

)

(11,077

)

Loss on extinguishment of debt

 

 

(7,567

)

Total other income (expense)

 

(8,510

)

(18,616

)

 

 

 

 

 

 

Income before income taxes

 

8,450

 

(7,963

)

 

 

 

 

 

 

Provision (benefit) for income taxes

 

4,443

 

(2,826

)

Net income (loss)

 

4,007

 

(5,137

)

 

 

 

 

 

 

Cumulative preferred dividends on Senior Preferred and Class B Preferred units

 

 

(3,619

)

 

 

 

 

 

 

Net income (loss) available to members and common shareholders

 

$

4,007

 

$

(8,756

)

 

 

 

 

 

 

Basic and diluted earnings (loss) per share

 

$

0.08

 

$

(0.33

)

 

 

 

 

 

 

Basic and diluted weighted average shares outstanding

 

49,997,647

 

26,515,916

 

 

See accompanying notes.

 

3



 

Prestige Brands Holdings, Inc.

Consolidated Statement of Changes in Stockholders’ Equity
and Comprehensive Income

Three Months Ended June 30, 2005

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

Common Stock

 

Additional

 

 

 

 

 

Other

 

 

 

 

 

(Dollars in thousands,

 

 

 

Par

 

Paid-in

 

Treasury Stock

 

Comprehensive

 

Retained

 

 

 

except share data)

 

Shares

 

Value

 

Capital

 

Shares

 

Amount

 

Income (Loss)

 

Earnings

 

Totals

 

Balances - March 31, 2005

 

50,000,000

 

$

500

 

$

378,251

 

2,353

 

$

(4

)

$

320

 

$

6,779

 

$

385,846

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional costs associated with initial public offering

 

 

 

 

 

(63

)

 

 

 

 

 

 

 

 

(63

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Components of comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

4,007

 

4,007

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on interest rate cap, net of income tax benefit of $440

 

 

 

 

 

 

 

 

 

 

 

(685

)

 

 

(685

)

Total comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,322

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances - June 30, 2005

 

50,000,000

 

$

500

 

$

378,188

 

2,353

 

$

(4

)

$

(365

)

$

10,786

 

$

389,105

 

 

See accompanying notes.

 

4



 

Prestige Brands Holdings, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

Three Months Ended June 30

 

(Dollars in thousands, except share data)

 

 

 

2005

 

2004

 

Operating Activities

 

 

 

 

 

Net income (loss)

 

$

4,007

 

$

(5,137

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

2,635

 

2,289

 

Deferred income taxes

 

4,338

 

2,913

 

Amortization of deferred financing costs

 

527

 

781

 

Loss on extinguishment of debt

 

 

7,567

 

Changes in operating assets and liabilities, net of effects of purchases of businesses

 

 

 

 

 

Accounts receivable

 

11,404

 

(5,861

)

Inventories

 

(6,366

)

5,200

 

Prepaid expenses and other assets

 

(887

)

(5,573

)

Accounts payable

 

(3,079

)

401

 

Account payable – related parties

 

 

934

 

Accrued expenses

 

(2,767

)

5,195

 

Net cash provided by operating activities

 

9,812

 

8,709

 

 

 

 

 

 

 

Investing Activities

 

 

 

 

 

Purchase of equipment

 

(206

)

(109

)

Purchase of business, net of cash acquired

 

 

(373,250

)

Net cash used for investing activities

 

(206

)

(373,359

)

 

 

 

 

 

 

Financing Activities

 

 

 

 

 

Proceeds from the issuance of notes

 

 

668,512

 

Payment of deferred financing costs

 

 

(22,651

)

Repayment of notes

 

(932

)

(330,786

)

Proceeds from the issuance of preferred and common units

 

 

58,487

 

Additional costs associated with initial public offering

 

(63

)

 

Net cash provided by (used for) financing activities

 

(995

)

373,562

 

 

 

 

 

 

 

Increase in cash

 

8,611

 

8,912

 

Cash - beginning of period

 

5,334

 

3,393

 

 

 

 

 

 

 

Cash - end of period

 

$

13,945

 

$

12,305

 

 

 

 

 

 

 

Supplemental Cash Flow Information

 

 

 

 

 

Fair value of assets acquired, net of cash acquired

 

$

 

$

596,955

 

Fair value of liabilities assumed

 

 

(223,613

)

Purchase price funded with non-cash contributions

 

 

(92

)

Cash paid to purchase business

 

$

 

$

373,250

 

 

 

 

 

 

 

Interest paid

 

$

8,051

 

$

10,295

 

Income taxes paid

 

$

422

 

$

280

 

 

See accompanying notes.

 

5



 

Prestige Brands Holdings, Inc.

Notes to Consolidated Financial Statements

(in thousands, except per share data)

 

1.              Business and Basis of Presentation

 

Nature of Business

 

Prestige Brands Holdings, Inc. (“the Company”) and its subsidiaries are engaged in the marketing, sales and distribution of over-the-counter drug, personal care and household cleaning brands to mass merchandisers, drug stores, supermarkets and club stores primarily in the United States.  In February 2005, the Company completed an initial public offering.

 

Basis of Presentation

 

The unaudited consolidated financial statements presented herein have been prepared in accordance with generally accepted accounting principles for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, the financial statements include all adjustments, consisting only of normal recurring adjustments that are considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods.  Operating results for the three month period ended June 30, 2005 are not necessarily indicative of results that may be expected for the year ending March 31, 2006.  This financial information should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K/A for the year ended March 31, 2005.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on the Company’s knowledge of current events and actions that the Company may undertake in the future, actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of the Company’s cash is held by one bank located in Wyoming.  The Company does not believe that, as a result of this concentration, it is subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.

 

Accounts Receivable

 

The Company extends non-interest bearing trade credit to its customers in the ordinary course of business. To minimize credit risk, ongoing evaluations of customers’ financial condition are performed; however, collateral is not required.  The Company maintains an allowance for doubtful accounts based on its historical collections experience, as well as its evaluation of current and expected conditions and trends affecting its customers.

 

Sales Returns

 

The Company must make estimates of potential future product returns related to current period sales. In order to do this, the Company analyzes historical returns, current economic trends, changes in customer demand and acceptance of the Company’s products when evaluating the adequacy of the Company’s allowance for returns in any accounting period.  If actual returns are greater than those estimated by management, the Company’s financial statements in future periods may be adversely affected.

 

6



 

Inventories

 

Inventories are stated at the lower of cost or fair value where cost is determined by using the first-in, first-out method.  The Company provides an allowance for slow moving and obsolete inventory.

 

Property and Equipment

 

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:

 

 

 

Years

 

Machinery

 

5

 

Computer equipment

 

3

 

Furniture and fixtures

 

7

 

 

Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statement of operations.

 

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

 

Goodwill

 

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in acquisition transactions is classified as goodwill.  In accordance with Financial Accounting Standards Board (“FASB”) Statement of Financial Accounting Standards (“SFAS”) No. 142, “Goodwill and Other Intangible Assets,” the Company does not amortize goodwill, but performs impairment tests of the carrying value at least annually.

 

Intangible Assets

 

Intangible assets are stated at the lesser of cost or fair value less accumulated amortization.  For intangible assets with finite lives, amortization is computed on the straight-line method over estimated useful lives ranging from five to 30 years.

 

Indefinite lived intangible assets are tested for impairment at least annually, while intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

 

Deferred Financing Costs

 

The Company has incurred debt issuance costs in connection with its long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method over the term of the related debt.

 

Revenue Recognition

 

Revenues are recognized when the following revenue recognition criteria are met: (1) persuasive evidence of an arrangement exists; (2) there is a fixed or determinable price; (3) the product has been shipped and the customer takes ownership and assumes risk of loss; and (4) collectibility of the resulting receivable is reasonably assured.  These criteria are satisfied upon shipment of product, and revenues are recognized accordingly.  Provision is made for estimated customer discounts and returns at the time of sale based on the Company’s historical experience.

 

The Company frequently participates in the promotional programs of its customers, as is customary in this industry.  The ultimate cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These programs may include coupons, scan downs, temporary price

 

7



 

reductions or other price guarantee vehicles.  The Company estimates the cost of such promotional programs at their inception based on historical experience and current market conditions and reduces sales by such estimates.  At the completion of the promotional program, the estimated amounts are adjusted to actual results.

 

Costs of Sales

 

Costs of sales include product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.  Shipping, warehousing and handling costs were $5.5 million and $5.3 million for the periods ended June 30, 2005 and 2004, respectively.

 

Advertising and Promotion Costs

 

Advertising and promotion costs are expensed as incurred.  Slotting fees associated with products are recognized as a reduction of sales.  Under slotting arrangements, the retailers allow the Company’s products to be placed on the stores’ shelves in exchange for such fees.  Direct reimbursements of advertising costs are reflected as a reduction of advertising costs in the period earned.

 

Stock-based Compensation

 

The Company accounts for employee stock-based compensation in accordance with the provisions of Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB 25”) and complies with the disclosure provisions of FASB Statement No. 123, “Accounting for Stock-Based Compensation” (“Statement No. 123”) and FASB Statement No. 148, “Accounting for Stock-Based Compensation—Transition and Disclosure, an amendment of FASB Statement No. 123.”  Under APB 25, compensation expense is based on the difference, if any, on the date of grant, between the fair value of the Company’s common stock and the exercise price of the equity instrument.

 

Income Taxes

 

Income taxes are recorded in accordance with the provisions of FASB Statement No. 109, “Accounting for Income Taxes” (“Statement No. 109”).  Pursuant to Statement No. 109, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

 

Derivative Instruments

 

FASB Statement No. 133, “Accounting for Derivative Instruments and Hedging Activities” (“Statement No. 133”), requires companies to recognize derivative instruments as either assets or liabilities in the balance sheet at fair value.  The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship.  For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, a cash flow hedge or a hedge of a net investment in an international operation.

 

The Company has designated its derivative financial instruments as cash flow hedges because they hedge exposure to variability in expected future cash flows that is attributable to interest rate risk.  For these hedges, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same line item associated with the forecasted transaction in the same period or periods during which the hedged transaction affects earnings. Any ineffective portion of the gain or loss on the derivative instruments is recorded in results of operations immediately.

 

Earnings Per Share

 

Basic and diluted earnings per share are calculated based on income (loss) available to common shareholders and the weighted-average number of shares outstanding during the reported period.  For the period ended June 30, 2004, the weighted average number of common shares outstanding includes the

 

8



 

Company’s common units as if the common units had been converted to common stock using the February 2005 initial public offering conversion ratio of one common unit to 0.4543 shares of common stock.  The Company had no potentially dilutive securities outstanding during the periods ended June 30, 2005 or June 30, 2004.

 

Recently Issued Accounting Standards

 

In March 2005, the FASB issued FASB Interpretation No. 47, “Accounting for Conditional Asset Retirement Obligations” (“FIN 47”) which clarifies guidance provided by Statement No. 143, “Accounting for Asset Retirement Obligations.”  FIN 47 is effective for the Company no later than March 31, 2006.  The adoption of FIN 47 is not expected to have a significant impact on the Company’s financial position, results of operations or cash flows.

 

In April 2005, the Securities and Exchange Commission approved an amendment to Rule 4-01 of Regulation S-X that delays the effective date of Statement No. 123 (Revised 2004), “Shared-Based Payments” (“Statement No. 123R”), which requires companies to expense the value of employee and director stock options and similar awards.  The Company is currently reviewing its options for implementation of Statement No. 123(R).  The results of operations for the period ended June 30, 2005 would not have been affected had the Company applied the fair value recognition provisions of Statement 123(R) during this period.

 

In May 2005, the FASB issued Statement of Financial Accounting Standards No. 154, “Accounting Changes and Error Corrections” (“Statement No. 154”) which replaces Accounting Principles Board Opinion No. 20, “Accounting Changes” (“APB Opinion No. 20”) and FASB Statement No. 3, “Reporting Accounting Changes in Interim Financial Statements.”  Statement No. 154 requires that voluntary changes in accounting principle be applied retrospectively to the balances of assets and liabilities as of the beginning of the earliest period for which retrospective application is practicable and that a corresponding adjustments be made to the opening balance of retained earnings.  APB Opinion No. 20 had required that most voluntary changes in accounting principle be recognized by including in net income the cumulative effect of changing to the new principle.  Statement No. 154 is effective for all accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005.

 

2.              Accounts Receivable

 

The components of accounts receivable consist of the following:

 

 

 

June 30, 2005

 

March 31, 2005

 

 

 

 

 

 

 

Accounts receivable

 

$

32,654

 

$

45,329

 

Other receivables

 

1,251

 

835

 

 

 

33,905

 

46,164

 

Less allowances for discounts, returns and uncollectible accounts

 

(1,416

)

(2,271

)

 

 

 

 

 

 

 

 

$

32,489

 

$

43,893

 

 

9



 

3.              Inventories

 

Inventories consist of the following:

 

 

 

June 30, 2005

 

March 31, 2005

 

 

 

 

 

 

 

Packaging and raw materials

 

$

5,192

 

$

3,587

 

Finished goods

 

22,754

 

17,993

 

 

 

 

 

 

 

 

 

$

27,946

 

$

21,580

 

 

Inventories are shown net of allowances for obsolete and slow moving inventory of $1.4 million at June 30, 2005 and March 31, 2005, respectively.

 

4.              Property and Equipment

 

Property and equipment consist of the following:

 

 

 

June 30, 2005

 

March 31, 2005

 

 

 

 

 

 

 

Machinery

 

$

2,828

 

$

2,828

 

Computer equipment

 

784

 

771

 

Furniture and fixtures

 

542

 

515

 

Leasehold improvements

 

339

 

173

 

 

 

4,493

 

4,287

 

 

 

 

 

 

 

Accumulated depreciation

 

(2,450

)

(1,963

)

 

 

 

 

 

 

 

 

$

2,043

 

$

2,324

 

 

5.              Intangible Assets

 

Intangible assets consist of the following:

 

 

 

June 30, 2005

 

 

 

Gross

 

Accumulated

 

Net

 

 

 

Amount

 

Amortization

 

Amount

 

 

 

 

 

 

 

 

 

Indefinite lived trademarks

 

$

522,346

 

$

 

$

522,346

 

 

 

 

 

 

 

 

 

Amortizable intangible assets

 

 

 

 

 

 

 

Trademarks

 

94,900

 

(10,915

)

83,985

 

Non-compete agreement

 

158

 

(24

)

134

 

 

 

95,058

 

(10,939

)

84,119

 

 

 

 

 

 

 

 

 

 

 

$

617,404

 

$

(10,939

)

$

606,465

 

 

10



 

 

 

March 31, 2005

 

 

 

Gross

 

Accumulated

 

Net

 

 

 

Amount

 

Amortization

 

Amount

 

 

 

 

 

 

 

 

 

Indefinite lived trademarks

 

$

522,346

 

$

 

$

522,346

 

 

 

 

 

 

 

 

 

Amortizable intangible assets

 

 

 

 

 

 

 

Trademarks

 

94,900

 

(8,775

)

86,125

 

Non-compete agreement

 

158

 

(16

)

142

 

 

 

95,058

 

(8,791

)

86,267

 

 

 

 

 

 

 

 

 

 

 

$

617,404

 

$

(8,791

)

$

608,613

 

 

At June 30, 2005, intangible assets are expected to be amortized over a period of five to 30 years as follows:

 

Twelve Months Ending June 30

 

 

 

 

 

 

2006

 

$

8,592

 

2007

 

8,592

 

2008

 

8,592

 

2009

 

8,592

 

2010

 

8,592

 

Thereafter

 

41,159

 

 

 

 

 

 

 

$

84,119

 

 

11



 

6.              Long-Term Debt

 

Long-term debt consists of the following:

 

 

 

June 30, 2005

 

March 31, 2005

 

 

 

 

 

 

 

Senior revolving credit facility (“Revolving Credit Facility”), which expires on April 6, 2009, is available for maximum borrowings of up to $60.0 million. The Revolving Credit Facility bears interest at the Company’s option at either the prime rate plus a variable margin or LIBOR plus a variable margin. The variable margin ranges from 0.75% to 2.50% and at June 30, 2005, the interest rate on the Revolving Credit Facility was 7.0% per annum. The Company is also required to pay a variable commitment fee on the unused portion of the Revolving Credit Facility. At June 30, 2005, the commitment fee was 0.50% of the unused line. The Revolving Credit Facility is collateralized by substantially all of the Company’s assets.

 

$

 

$

 

 

 

 

 

 

 

Senior secured term loan facility, (“Tranche B Term Loan Facility”) bears interest at the Company’s option at either the prime rate or LIBOR plus a variable margin of 2.25%. At June 30, 2005, the applicable interest rate on the Tranche B Term Loan Facility was 5.38%. Principal payments of $933 and interest are payable quarterly. In February 2005, the Tranche B Term Loan Facility was amended to increase the amount available thereunder by $200.0 million, all of which is available at June 30, 2005. Current amounts outstanding under the Tranche B Term Loan Facility mature on April 6, 2011, while amounts borrowed pursuant to the amendment will mature on October 6, 2011. The Tranche B Term Loan Facility is collateralized by substantially all of the Company’s assets.

 

368,428

 

369,360

 

 

 

 

 

 

 

Senior Subordinated Notes (“Senior Notes”) that bear interest at 9.25% which is payable on April 15th and October 15th of each year. The Senior Notes mature on April 15, 2012; however, the Company may redeem some or all of the Senior Notes on or prior to April 15, 2008 at a redemption price equal to 100% plus a make-whole premium, and on or after April 15, 2008 at redemption prices set forth in the indenture governing the Senior Notes. The Senior Notes are unconditionally guaranteed by Prestige Brands International, LLC (“Prestige International”), a wholly owned subsidiary, and Prestige International’s wholly owned subsidiaries (other than the issuer). There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries.

 

126,000

 

126,000

 

 

 

 

 

 

 

 

 

494,428

 

495,360

 

Current portion of long-term debt

 

(3,730

)

(3,730

)

 

 

 

 

 

 

 

 

$

490,698

 

$

491,630

 

 

12



 

The Revolving Credit Facility and the Tranche B Term Loan Facility (together the “Senior Credit Facility”) contain various financial covenants, including provisions that require the Company to maintain certain leverage ratios, interest coverage ratios and fixed charge coverage ratios.  Additionally, the Senior Credit Facility contains provisions that restrict the Company from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, changes of control, incurrence of indebtedness, creation of liens and transactions with affiliates.  The Company was in compliance with its financial and restrictive covenants under the Senior Credit Facility at June 30, 2005.

 

Future principal payments required in accordance with the terms of the Senior Credit Facility and the Senior Notes are as follows:

 

Twelve Months Ending June 30

 

 

 

 

 

 

2006

 

$

3,730

 

2007

 

3,730

 

2008

 

3,730

 

2009

 

3,730

 

2010

 

3,730

 

Thereafter

 

475,778

 

 

 

 

 

 

 

$

494,428

 

 

The Company entered into a 5% interest rate cap agreement with a financial institution to mitigate the impact of changing interest rates.  The agreement provides for a notional amount of $20.0 million and terminates in June 2006.  The Company also entered into interest rate cap agreements with another financial institution that become effective August 30, 2005, with a total notional amount of $180.0 million and cap rates ranging from 3.25% to 3.75%.  The agreements terminate on May 30, 2006, 2007 and 2008 as to $50.0 million, $80.0 million and $50.0 million, respectively.  The Company is accounting for the interest rate cap agreements as cash flow hedges.  The fair value of the interest rate cap agreements was $1.7 million at June 30, 2005.

 

7.              Commitments and Contingencies

 

In July 2002, the Company entered into a ten year manufacturing and supply agreement with an unrelated company.  Pursuant to this agreement, the Company agreed to purchase certain minimum quantities of product over the initial three years of the agreement or to pay liquidated damages of up to $360.  The Company had recorded a liability of $308 at June 30, 2005 and March 31, 2005, which represents its estimate of the probable liquidated damages.  Such estimate is based on historical and expected purchases during the initial three years of the agreement.

 

In June 2003, Dr. Jason Theodosakis filed a lawsuit, Theodosakis v. Walgreens, et al., in Federal District Court in Arizona, alleging that two of the Company’s subsidiaries, Medtech Products and Pecos Pharmaceutical, as well as other unrelated parties, infringed the trade dress of two of his published books.  Specifically, Dr. Theodosakis published “The Arthritis Cure” and “Maximizing the Arthritis Cure” regarding the use of dietary supplements to treat arthritis patients.  Dr. Theodosakis alleged that his books have a distinctive trade dress, or cover layout, design, color and typeface, and those products that the defendants sold under the ARTHx trademarks infringed the books’ trade dress and constituted unfair competition and false designation of origin.  Additionally, Dr. Theodosakis alleged that the defendants made false endorsements of the products by referencing his books on the product packaging and that the use of his name, books and trade dress invaded his right to publicity.  The Company sold the ARTHx trademarks, goodwill and inventory to a third party, Contract Pharmacal Corporation, in March 2003.  On January 12, 2005, the court granted the Company’s motion for summary judgment and dismissed all

 

13



 

claims against Pecos and Medtech.  The plaintiff has filed an appeal in the U.S. Court of Appeals which is pending.

 

On January 3, 2005, the Company was served with process by its former lead counsel in the Theodosakis litigation seeking $679 plus interest.  The case was filed in the Supreme Court of New York and is styled as Dickstein Shapiro et al v. Medtech Products, Inc.  In February 2005, the plaintiffs filed an amended complaint naming the Pecos Pharmaceutical Company as defendant.  The Company has answered and filed a counterclaim against Dickstein and also filed a third party complaint against the Lexington Insurance Company.  The Company believes that if there is any obligation to the Dickstein firm relating to this matter, it is an obligation of Lexington and not the Company.

 

On May 9, 2005, the Company was served with a complaint in a class action lawsuit filed in Essex County, Massachusetts, styled as Dawn Thompson v. Wyeth, Inc. relating to the Company’s Little Remedies pediatric cough products.  The Company is one of several corporate defendants, all of whom market over-the-counter cough syrup products for pediatric use.  The complaint alleges that the ingredient dextromethorphan is no more effective than a placebo.  There is no allegation of physical injury caused by the product or the ingredient.  In June 2005, the Company was served in a second class action complaint involving dextromethorphan.  The second case, styled Tina Yescavage v. Wyeth was filed in Lee County Florida and similarly involves multiple corporate defendants.  The Company believes that both of the dextromethorphan cases are without merit and is actively pursuing appropriate defenses.  The use of dextromethorphan in pediatric products is fully consistent with and supported by Food and Drug Administration regulations.

 

The Company is also involved from time to time in routine legal matters and other claims incidental to its business. When it appears probable in management’s judgment that the Company will incur monetary damages or other costs in connection with such claims and proceedings, and such costs can be reasonably estimated, liabilities are recorded in the financial statements and charges are recorded against earnings. The Company believes the resolution of such routine matters and other incidental claims, taking into account reserves and insurance, will not have a material adverse effect on its financial condition or results of operation.

 

8.              Equity Incentive Plan

 

In connection with the Company’s IPO, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (“the Plan”).  The Plan provides for grants of stock options, restricted stock, restricted stock units, deferred stock units and other equity-based awards.  Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.  At June 30, 2005, there were 5,000,000 shares available for issuance under the Plan; however, no grants have been made under the Plan.

 

9.              Related Party Transactions

 

The Company had entered in an agreement with an affiliate of GTCR Golder Rauner II, LLC (“GTCR”), a private equity firm and an investor in the Company, whereby the GTCR affiliate was to provide

 

14



 

management and advisory services to the Company for an aggregate annual compensation of $4.0 million.  The agreement was terminated in February 2005.  During the period ended June 30, 2004, the Company paid the affiliate of GTCR a management fee of $934.

 

10.       Income Taxes

 

Income taxes are recorded in the Company’s quarterly financial statements based on the Company’s estimated annual effective income tax rate.  The effective rates used in the calculation of income taxes were 52.6% and 35.5% for the periods ended June 30, 2005 and 2004, respectively.  The increase in the effective tax rate for 2005 resulted primarily from a one time charge of approximately $1.2 million due to the increase in the Company’s graduated federal income tax rate from 34% to 35% and its related impact on the Company’s deferred tax liabilities.

 

11.       Concentrations of Risk

 

The Company’s sales are concentrated in the areas of over-the-counter pharmaceutical products, personal care products and household cleaning products.  The Company sells its products to mass merchandisers, food and drug accounts, and dollar and club stores.  During the period ended June 30, 2005, approximately 60.8% of the Company’s total sales were derived from its four major brands while during the period ended June 30, 2004, approximately 64.4% of the Company’s total sales were derived from these four brands.  During the periods ended June 30, 2005 and 2004, approximately 22.8% and 23.3%, respectively, of the Company’s net sales were made to one customer.  At June 30, 2005, approximately 20% of accounts receivable were owed by one customer.

 

The Company manages product distribution in the continental United States through a main distribution center in St. Louis, Missouri.  A serious disruption, such as a flood or fire, to the main distribution center could damage the Company’s inventory and could materially impair the Company’s ability to distribute its products to customers in a timely manner or at a reasonable cost.  The Company could incur significantly higher costs and experience longer lead times associated with the distribution of its products to its customers during the time that it takes the Company to reopen or replace its distribution center.  As a result, any such disruption could have a material adverse effect on the Company’s sales and profitability.

 

12.       Business Segments

 

Segment information has been prepared in accordance with FASB Statement No. 131, “Disclosures about Segments of an Enterprise and Related Information.”  The Company’s operating segments are based on its product lines and consist of (i) Over-the-Counter Drugs, (ii) Personal Care and (iii) Household Cleaning.  Accordingly, within each reportable segment are operations that have similar economic characteristics, including the nature of their products, production process, type of customer and method of distribution.

 

There were no inter-segment sales or transfers during the periods ended June 30, 2005 and 2004.  The Company evaluates the performance of its product lines and allocates resources to them based primarily on contribution margin.  The table below summarizes information about reportable segments.

 

15



 

 

 

Period Ended June 30, 2005

 

 

 

Over-the-
Counter

 

Personal

 

Household

 

 

 

 

 

Drug

 

Care

 

Cleaning

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

32,866

 

$

7,484

 

$

23,180

 

$

63,530

 

Other revenues

 

 

 

25

 

25

 

 

 

 

 

 

 

 

 

 

 

Total revenues

 

32,866

 

7,484

 

23,205

 

63,555

 

Cost of sales

 

11,165

 

3,884

 

13,290

 

28,339

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

21,701

 

3,600

 

9,915

 

35,216

 

Advertising and promotion

 

7,402

 

1,103

 

2,209

 

10,714

 

 

 

 

 

 

 

 

 

 

 

Contribution margin

 

$

14,299

 

$

2,497

 

$

7,706

 

24,502

 

Other operating expenses

 

 

 

 

 

 

 

7,542

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

 

 

 

 

 

 

16,960

 

Other income (expense)

 

 

 

 

 

 

 

(8,510

)

Provision for income taxes

 

 

 

 

 

 

 

(4,443

)

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

$

4,007

 

 

 

 

Period Ended June 30, 2004

 

 

 

Over-the-

 

 

 

 

 

 

 

 

 

Counter

 

Personal

 

Household

 

 

 

 

 

Drug

 

Care

 

Cleaning

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

34,599

 

$

8,438

 

$

24,645

 

$

67,682

 

Other revenues

 

 

 

 

 

75

 

75

 

 

 

 

 

 

 

 

 

 

 

Total revenues

 

34,599

 

8,438

 

24,720

 

67,757

 

Cost of sales

 

14,722

 

4,445

 

16,956

 

36,123

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

19,877

 

3,993

 

7,764

 

31,634

 

Advertising and promotion

 

7,989

 

2,621

 

3,161

 

13,771

 

 

 

 

 

 

 

 

 

 

 

Contribution margin

 

$

11,888

 

$

1,372

 

$

4,603

 

17,863

 

Other operating expenses

 

 

 

 

 

 

 

7,210

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

 

 

 

 

 

 

10,653

 

Other income (expense)

 

 

 

 

 

 

 

(18,616

)

Benefit for income taxes

 

 

 

 

 

 

 

2,826

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

$

(5,137

)

 

During the periods ended June 30, 2005 and 2004, 97.9% and 97.4%, respectively, of sales were made to customers in the United States and Canada.  No individual geographical area accounted for more than 10% of net sales in any of the periods presented.  At June 30, 2005 and 2004, all of the Company’s long-term assets were located in the United States of America and have not been allocated between segments.

 

16



 

13.       Subsequent Events

 

On July 22, 2005, the Company entered into a material definitive asset sale and purchase agreement with Reckitt Benckiser Inc. for the acquisition of the Chore Boy line of household cleaning products for an aggregate consideration of $22.3 million.

 

Pursuant to the provisions of the Company’s 2005 Long-Term Equity Incentive Plan, on July 29, 2005, each of the Company’s four independent members of the Board of Directors received an award of 6,222 shares of common stock in connection with Company’s directors’ compensation arrangements.  Of such amount, 1,778 shares represent a one-time grant of unrestricted shares while the remaining 4,444 shares represent restricted shares that vest over a two year period.

 

On August 3, 2005, a complaint in a class action lawsuit, Charter Township of Clinton Police and Fire Retirement System v. Prestige Brands Holdings, Inc. et al, was filed in United States District Court for the Southern District of New York, on behalf of all persons who purchased the Company’s securities pursuant to and/or traceable to the Company’s initial public offering (the “IPO”) on or about February 9, 2005 through July 28, 2005.  The complaint also names as defendants Merrill Lynch, Pierce, Fenner & Smith Incorporated, Goldman, Sachs & Co and J.P. Morgan Securities Inc., the lead or co-lead underwriters of the IPO.  The complaint charges the Company, certain of its officers and directors, and other insiders with violations of the Securities Act of 1933.  The Company plans to defend this matter vigorously.

 

The Company has been made aware of the possibility of additional similar class action lawsuits.  If these potential lawsuits are filed, the Company plans to defend these matters vigorously.

 

On August 4, 2005, Frank Palantoni joined the Company as President and Chief Operating Officer.  In connection therewith, the Board of Directors granted Mr. Palantoni 30,888 shares of restricted common stock and options to purchase an additional 61,776 shares of common stock at a purchase price of $12.95 per share.  The options vest over a period of five years while the restricted shares will vest contingent upon the attainment of certain performance-based benchmarks.

 

17



 

Prestige Brands International, LLC

Consolidated Balance Sheets

(Unaudited)

 

(Dollars in thousands, except share data)

 

 

 

June 30, 2005

 

March 31, 2005

 

Assets

 

 

 

 

 

Current assets

 

 

 

 

 

Cash

 

$

13,945

 

$

5,334

 

Accounts receivable

 

32,489

 

43,893

 

Inventories

 

27,946

 

21,580

 

Deferred income tax assets

 

6,965

 

5,699

 

Prepaid expenses and other current assets

 

4,039

 

3,152

 

Total current assets

 

85,384

 

79,658

 

 

 

 

 

 

 

Property and equipment

 

2,043

 

2,324

 

Goodwill

 

294,544

 

294,544

 

Intangible assets

 

606,465

 

608,613

 

Other long-term assets

 

14,344

 

15,996

 

 

 

 

 

 

 

Total Assets

 

$

1,002,780

 

$

1,001,135

 

 

 

 

 

 

 

Liabilities and Members’ Equity

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable

 

$

18,626

 

$

21,705

 

Accrued liabilities

 

10,705

 

13,472

 

Current portion of long-term debt

 

3,730

 

3,730

 

Total current liabilities

 

33,061

 

38,907

 

 

 

 

 

 

 

Long-term debt

 

490,698

 

491,630

 

Deferred income tax liabilities

 

89,916

 

84,752

 

 

 

 

 

 

 

Total liabilities

 

613,675

 

615,289

 

 

 

 

 

 

 

Commitments and Contingencies – Note 7

 

 

 

 

 

 

 

 

 

 

 

Members’ Equity

 

 

 

 

 

Contributed capital – Prestige Holdings

 

370,214

 

370,277

 

Accumulated other comprehensive income (loss)

 

(365

)

320

 

Retained earnings

 

19,256

 

15,249

 

Total members’ equity

 

389,105

 

385,846

 

 

 

 

 

 

 

Total liabilities and members’ equity

 

$

1,002,780

 

$

1,001,135

 

 

See accompanying notes.

 

18



 

Prestige Brands International, LLC

Consolidated Statements of Operations

(Unaudited)

 

 

 

Three Months Ended June 30

 

(Dollars in thousands, except share data

 

 

 

2005

 

2004

 

Revenues

 

 

 

 

 

Net sales

 

$

63,530

 

$

67,682

 

Other revenues

 

25

 

75

 

Total revenues

 

63,555

 

67,757

 

 

 

 

 

 

 

Costs of Sales

 

 

 

 

 

Costs of sales

 

28,339

 

36,123

 

Gross profit

 

35,216

 

31,634

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

Advertising and promotion

 

10,714

 

13,771

 

General and administrative

 

4,911

 

4,921

 

Depreciation

 

483

 

486

 

Amortization of intangible assets

 

2,148

 

1,803

 

Total operating expenses

 

18,256

 

20,981

 

 

 

 

 

 

 

Operating income

 

16,960

 

10,653

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

Interest income

 

81

 

28

 

Interest expense

 

(8,591

)

(11,077

)

Loss on extinguishment of debt

 

 

(7,567

)

Total other income (expense)

 

(8,510

)

(18,616

)

 

 

 

 

 

 

Income before income taxes

 

8,450

 

(7,963

)

 

 

 

 

 

 

Provision (benefit) for income taxes

 

4,443

 

(2,826

)

 

 

 

 

 

 

Net income (loss)

 

$

4,007

 

$

(5,137

)

 

See accompanying notes.

 

19



 

Prestige Brands International, LLC

Consolidated Statement of Changes in Members’ Equity
and Comprehensive Income

Three Months Ended June 30, 2005

(Unaudited)

 

(Dollars in thousands, expect share data)

 

 

Contributed
Capital
Prestige
Holdings

 

Accumulated
Other
Comprehensive
Income (loss)

 

Retained
Earnings

 

Totals

 

Balances - March 31, 2005

 

$

370,277

 

$

320

 

$

15,249

 

$

385,846

 

 

 

 

 

 

 

 

 

 

 

Additional costs associated with capital contributions from Prestige Brands Holdings

 

(63

)

 

 

 

 

(63

)

 

 

 

 

 

 

 

 

 

 

Components of comprehensive income

 

 

 

 

 

 

 

 

 

Net income for the period

 

 

 

 

 

4,007

 

4,007

 

Unrealized loss on interest rate cap, net of income tax benefit of $440

 

 

 

(685

)

 

 

(685

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,322

 

 

 

 

 

 

 

 

 

 

 

Balances - June 30, 2005

 

$

370,214

 

$

(365

)

$

19,256

 

$

389,105

 

 

See accompanying notes.

 

20



 

Prestige Brands International, LLC

Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

Three Months Ended June 30

 

(Dollars in thousands, except share data)

 

 

 

2005

 

2004

 

Operating Activities

 

 

 

 

 

Net income (loss)

 

$

4,007

 

$

(5,137

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

2,635

 

2,289

 

Deferred income taxes

 

4,338

 

2,913

 

Amortization of deferred financing costs

 

527

 

781

 

Loss on extinguishment of debt

 

 

7,567

 

Changes in operating assets and liabilities, net of effects of purchases of businesses

 

 

 

 

 

Accounts receivable

 

11,404

 

(5,861

)

Inventories

 

(6,366

)

5,200

 

Prepaid expenses and other assets

 

(887

)

(5,573

)

Accounts payable

 

(3,079

)

401

 

Account payable – related parties

 

 

934

 

Accrued expenses

 

(2,767

)

5,195

 

Net cash provided by operating activities

 

9,812

 

8,709

 

 

 

 

 

 

 

Investing Activities

 

 

 

 

 

Purchase of equipment

 

(206

)

(109

)

Purchase of business, net of cash acquired

 

 

(373,250

)

Net cash used for investing activities

 

(206

)

(373,359

)

 

 

 

 

 

 

Financing Activities

 

 

 

 

 

Net proceeds from the issuance of notes

 

 

668,512

 

Payment of deferred financing costs

 

 

(22,651

)

Repayment of notes

 

(932

)

(330,786

)

Proceeds from capital contributions

 

 

58,487

 

Additional costs associated with initial public offering

 

(63

)

 

Net cash provided by (used for) financing activities

 

(995

)

373,562

 

 

 

 

 

 

 

Increase in cash

 

8,611

 

8,912

 

Cash – beginning of period

 

5,334

 

3,393

 

 

 

 

 

 

 

Cash – end of period

 

$

13,945

 

$

12,305

 

 

 

 

 

 

 

Supplemental Cash Flow Information

 

 

 

 

 

Fair value of assets acquired, net of cash acquired

 

$

 

$

596,955

 

Fair value of liabilities assumed

 

 

(223,613

)

Purchase price funded with non-cash contributions

 

 

(92

)

Cash paid to purchase business

 

$

 

$

373,250

 

 

 

 

 

 

 

Interest paid

 

$

8,051

 

$

10,295

 

Income taxes paid

 

$

422

 

$

280

 

 

See accompanying notes.

 

21



 

Prestige Brands International, LLC

Notes to Consolidated Financial Statements

(in thousands, except per share data)

 

1.              Business and Basis of Presentation

 

Nature of Business

 

Prestige Brands International, LLC, (“Prestige International”) is an indirect wholly owned subsidiary of Prestige Brands Holdings, Inc. (“the Company”) and the indirect parent company of Prestige Brands, Inc., the issuer of the 9.25% senior subordinated notes due 2012 (“Senior Notes”) and the borrower under the senior credit facility consisting of a Revolving Credit Facility, Tranche B Term Loan Facility and a Tranche C Term Loan Facility (together the “Senior Credit Facility”).  Prestige International is also the parent guarantor of the obligations.  The Company and its subsidiaries are engaged in the marketing, sales and distribution of over-the-counter drug, personal care and household cleaning brands to mass merchandisers, drug stores, supermarkets and club stores primarily in the United States.

 

Basis of Presentation

 

The unaudited consolidated financial statements presented herein have been prepared in accordance with generally accepted accounting principles for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, the financial statements include all adjustments, consisting only of normal recurring adjustments that are considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods.  Operating results for the three month period ended June 30, 2005 are not necessarily indicative of results that may be expected for the year ending March 31, 2006.  This financial information should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K/A for the year ended March 31, 2005.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on the Company’s knowledge of current events and actions that the Company may undertake in the future, actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of the Company’s cash is held by one bank located in Wyoming.  The Company does not believe that, as a result of this concentration, it is subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.

 

Accounts Receivable

 

The Company extends non-interest bearing trade credit to its customers in the ordinary course of business. To minimize credit risk, ongoing evaluations of customers’ financial condition are performed; however, collateral is not required.  The Company maintains an allowance for doubtful accounts based on its historical collections experience, as well as its evaluation of current and expected conditions and trends affecting its customers.

 

22



 

Sales Returns

 

The Company must make estimates of potential future product returns related to current period sales. In order to do this, the Company analyzes historical returns, current economic trends, changes in customer demand and acceptance of the Company’s products when evaluating the adequacy of the Company’s allowance for returns in any accounting period.  If actual returns are greater than those estimated by management, the Company’s financial statements in future periods may be adversely affected.

 

Inventories

 

Inventories are stated at the lower of cost or fair value where cost is determined by using the first-in, first-out method.  The Company provides an allowance for slow moving and obsolete inventory.

 

Property and Equipment

 

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:

 

 

 

Years

 

Machinery

 

5

 

Computer equipment

 

3

 

Furniture and fixtures

 

7

 

 

Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statement of operations.

 

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

 

Goodwill

 

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in acquisition transactions is classified as goodwill.  In accordance with Statement No. 142, “Goodwill and Other Intangible Assets,” the Company does not amortize goodwill, but performs impairment tests of the carrying value at least annually.

 

Intangible Assets

 

Intangible assets are stated at the lesser of cost or fair value less accumulated amortization.  For intangible assets with finite lives, amortization is computed on the straight-line method over estimated useful lives ranging from five to 30 years.

 

Indefinite lived intangible assets are tested for impairment at least annually, while intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

 

Deferred Financing Costs

 

The Company has incurred debt issuance costs in connection with its long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method over the term of the related debt.

 

Revenue Recognition

 

Revenues are recognized when the following revenue recognition criteria are met: (1) persuasive evidence of an arrangement exists; (2) there is a fixed or determinable price; (3) the product has been shipped and the customer takes ownership and assumes risk of loss; and (4) collectibility of the resulting receivable is reasonably assured.  These criteria are satisfied upon shipment of product, and revenues are recognized

 

23



 

accordingly.  Provision is made for estimated customer discounts and returns at the time of sale based on the Company’s historical experience.

 

The Company frequently participates in the promotional programs of its customers, as is customary in this industry.  The ultimate cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These programs may include coupons, scan downs, temporary price reductions or other price guarantee vehicles.  The Company estimates the cost of such promotional programs at their inception based on historical experience and current market conditions and reduces sales by such estimates.  At the completion of the promotional program, the estimated amounts are adjusted to actual results.

 

Costs of Sales

 

Costs of sales include product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.  Shipping, warehousing and handling costs were $5.5 million and $5.3 million for the periods ended June 30, 2005 and 2004, respectively.

 

Advertising and Promotion Costs

 

Advertising and promotion costs are expensed as incurred.  Slotting fees associated with products are recognized as a reduction of sales.  Under slotting arrangements, the retailers allow the Company’s products to be placed on the stores’ shelves in exchange for such fees.  Direct reimbursements of advertising costs are reflected as a reduction of advertising costs in the period earned.

 

Stock-based Compensation

 

The Company accounts for employee stock-based compensation in accordance with the provisions of APB 25 and complies with the disclosure provisions of Statement No. 123 and Statement No. 148.  Under APB 25, compensation expense is based on the difference, if any, on the date of grant, between the fair value of the Company’s common stock and the exercise price of the equity instrument.

 

Income Taxes

 

Income taxes are recorded in accordance with the provisions of Statement No. 109.  Pursuant to Statement No. 109, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

 

Derivative Instruments

 

Statement No. 133 requires companies to recognize derivative instruments as either assets or liabilities in the balance sheet at fair value.  The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship.  For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, a cash flow hedge or a hedge of a net investment in an international operation.

 

The Company has designated its derivative financial instruments as cash flow hedges because they hedge exposure to variability in expected future cash flows that is attributable to interest rate risk.  For these hedges, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same line item associated with the forecasted transaction in the same period or periods during which the hedged transaction affects earnings. Any ineffective portion of the gain or loss on the derivative instruments is recorded in results of operations immediately.

 

24



 

Recently Issued Accounting Standards

 

In March 2005, the FASB issued FIN 47 which clarifies guidance provided by Statement No. 143, “Accounting for Asset Retirement Obligations.”  FIN 47 is effective for the Company no later than March 31, 2006.  The adoption of FIN 47 is not expected to have a significant impact on the Company’s financial position, results of operations or cash flows.

 

In April 2005, the Securities and Exchange Commission approved an amendment to Rule 4-01 of Regulation S-X that delays the effective date of Statement No. 123(R) which requires companies to expense the value of employee and director stock options and similar awards.  The Company is currently reviewing its options for implementation of Statement No. 123(R).  The results of operations for the period ended June 30, 2005 would not have been affected had the Company applied the fair value recognition provisions of Statement 123(R) during this period.

 

In May 2005, the FASB issued Statement No. 154 which replaces APB Opinion No. 20 and FASB Statement No. 3, “Reporting Accounting Changes in Interim Financial Statements.”  Statement No. 154 requires that voluntary changes in accounting principle be applied retrospectively to the balances of assets and liabilities as of the beginning of the earliest period for which retrospective application is practicable and that a corresponding adjustments be made to the opening balance of retained earnings.  APB Opinion No. 20 had required that most voluntary changes in accounting principle be recognized by including in net income the cumulative effect of changing to the new principle.  Statement No. 154 is effective for all accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005.

 

2.              Accounts Receivable

 

The components of accounts receivable consist of the following:

 

 

 

June 30, 2005

 

March 31, 2005

 

 

 

 

 

 

 

Accounts receivable

 

$

32,654

 

$

45,329

 

Other receivables

 

1,251

 

835

 

 

 

33,905

 

46,164

 

Less allowances for discounts, returns and uncollectible accounts

 

(1,416

)

(2,271

)

 

 

 

 

 

 

 

 

$

32,489

 

$

43,893

 

 

3.              Inventories

 

Inventories consist of the following:

 

 

 

June 30, 2005

 

March 31, 2005

 

 

 

 

 

 

 

Packaging and raw materials

 

$

5,192

 

$

3,587

 

Finished goods

 

22,754

 

17,993

 

 

 

 

 

 

 

 

 

$

27,946

 

$

21,580

 

 

Inventories are shown net of allowances for obsolete and slow moving inventory of $1.4 million at June 30, 2005 and March 31, 2005, respectively.

 

25



 

4.              Property and Equipment

 

Property and equipment consist of the following:

 

 

 

June 30, 2005

 

March 31, 2005

 

 

 

 

 

 

 

Machinery

 

$

2,828

 

$

2,828

 

Computer equipment

 

784

 

771

 

Furniture and fixtures

 

542

 

515

 

Leasehold improvements

 

339

 

173

 

 

 

4,493

 

4,287

 

 

 

 

 

 

 

Accumulated depreciation

 

(2,450

)

(1,963

)

 

 

 

 

 

 

 

 

$

2,043

 

$

2,324

 

 

5.              Intangible Assets

 

Intangible assets consist of the following:

 

 

 

June 30, 2005

 

 

 

Gross

 

Accumulated

 

Net

 

 

 

Amount

 

Amortization

 

Amount

 

 

 

 

 

 

 

 

 

Indefinite lived trademarks

 

$

522,346

 

$

 

$

522,346

 

 

 

 

 

 

 

 

 

Amortizable intangible assets

 

 

 

 

 

 

 

Trademarks

 

94,900

 

(10,915

)

83,985

 

Non-compete agreement

 

158

 

(24

)

134

 

 

 

95,058

 

(10,939

)

84,119

 

 

 

 

 

 

 

 

 

 

 

$

617,404

 

$

(10,939

)

$

606,465

 

 

 

 

March 31, 2005

 

 

 

Gross

 

Accumulated

 

Net

 

 

 

Amount

 

Amortization

 

Amount

 

 

 

 

 

 

 

 

 

Indefinite lived trademarks

 

$

522,346

 

$

 

$

522,346

 

 

 

 

 

 

 

 

 

Amortizable intangible assets

 

 

 

 

 

 

 

Trademarks

 

94,900

 

(8,775

)

86,125

 

Non-compete agreement

 

158

 

(16

)

142

 

 

 

95,058

 

(8,791

)

86,267

 

 

 

 

 

 

 

 

 

 

 

$

617,404

 

$

(8,791

)

$

608,613

 

 

26



 

At June 30, 2005, intangible assets are expected to be amortized over a period of five to 30 years as follows:

 

Twelve Months Ending June 30

 

 

 

 

 

 

2006

 

 

 

 

$

8,592

 

2007

 

8,592

 

2008

 

8,592

 

2009

 

8,592

 

2010

 

8,592

 

Thereafter

 

41,159

 

 

 

 

 

 

 

$

84,119

 

 

27



 

6.              Long-Term Debt

 

Long-term debt consists of the following:

 

 

 

June 30, 2005

 

March 31, 2005

 

 

 

 

 

 

 

Senior revolving credit facility (“Revolving Credit Facility”), which expires on April 6, 2009, is available for maximum borrowings of up to $60.0 million. The Revolving Credit Facility bears interest at the Company’s option at either the prime rate plus a variable margin or LIBOR plus a variable margin. The variable margin ranges from 0.75% to 2.50% and at June 30, 2005, the interest rate on the Revolving Credit Facility was 7.0% per annum. The Company is also required to pay a variable commitment fee on the unused portion of the Revolving Credit Facility. At June 30, 2005, the commitment fee was 0.50% of the unused line. The Revolving Credit Facility is collateralized by substantially all of the Company’s assets.

 

$

 

$

 

 

 

 

 

 

 

Senior secured term loan facility, (“Tranche B Term Loan Facility”) bears interest at the Company’s option at either the prime rate or LIBOR plus a variable margin of 2.25%. At June 30, 2005, the applicable interest rate on the Tranche B Term Loan Facility was 5.38%. Principal payments of $933 and interest are payable quarterly. In February 2005, the Tranche B Term Loan Facility was amended to increase the amount available thereunder by $200.0 million, all of which is available at June 30, 2005. Current amounts outstanding under the Tranche B Term Loan Facility mature on April 6, 2011, while amounts borrowed pursuant to the amendment will mature on October 6, 2011. The Tranche B Term Loan Facility is collateralized by substantially all of the Company’s assets.

 

368,428

 

369,360

 

 

 

 

 

 

 

Senior Subordinated Notes (Senior Notes) that bear interest at 9.25% which is payable on April 15th and October 15th of each year. The Senior Notes mature on April 15, 2012; however, the Company may redeem some or all of the Senior Notes on or prior to April 15, 2008 at a redemption price equal to 100% plus a make-whole premium, and on or after April 15, 2008 at redemption prices set forth in the indenture governing the Senior Notes. The Senior Notes are unconditionally guaranteed by Prestige International and Prestige International’s wholly owned subsidiaries (other than the issuer). There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries.

 

126,000

 

126,000

 

 

 

 

 

 

 

 

 

494,428

 

495,360

 

Current portion of long-term debt

 

(3,730)

 

(3,730)

 

 

 

 

 

 

 

 

 

$

490,698

 

$

491,630

 

 

28



 

The Revolving Credit Facility and the Tranche B Term Loan Facility (together the “Senior Credit Facility”) contain various financial covenants, including provisions that require the Company to maintain certain leverage ratios, interest coverage ratios and fixed charge coverage ratios.  Additionally, the Senior Credit Facility contains provisions that restrict the Company from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, changes of control, incurrence of indebtedness, creation of liens and transactions with affiliates.  The Company was in compliance with its financial and restrictive covenants under the Senior Credit Facility at June 30, 2005.

 

Future principal payments required in accordance with the terms of the Senior Credit Facility and the Senior Notes are as follows:

 

Twelve Months Ending June 30

 

 

 

 

 

 

2006

 

$

3,730

 

2007

 

3,730

 

2008

 

3,730

 

2009

 

3,730

 

2010

 

3,730

 

Thereafter

 

475,778

 

 

 

 

 

 

 

$

494,428

 

 

The Company entered into a 5% interest rate cap agreement with a financial institution to mitigate the impact of changing interest rates.  The agreement provides a notional amount of $20.0 million and terminates in June 2006.  The Company also entered into interest rate cap agreements with another financial institution that become effective August 30, 2005, with a total notional amount of $180.0 million and cap rates ranging from 3.25% to 3.75%.  The agreements terminate on May 30, 2006, 2007 and 2008 as to $50.0 million, $80.0 million and $50.0 million, respectively.  The Company is accounting for the interest rate cap agreements as cash flow hedges.  The fair value of the interest rate cap agreements was $1.7 million at June 30, 2005.

 

7.              Commitments and Contingencies

 

In July 2002, the Company entered into a ten year manufacturing and supply agreement with an unrelated company.  Pursuant to this agreement, the Company agreed to purchase certain minimum quantities of product over the initial three years of the agreement or to pay liquidated damages of up to $360.  The Company had recorded a liability of $308 at June 30, 2005 and March 31, 2005 which represents its estimate of the probable liquidated damages.  Such estimate is based on historical and expected purchases during the initial three years of the agreement.

 

In June 2003, Dr. Jason Theodosakis filed a lawsuit, Theodosakis v. Walgreens, et al., in Federal District Court in Arizona, alleging that two of the Company’s subsidiaries, Medtech Products and Pecos Pharmaceutical, as well as other unrelated parties, infringed the trade dress of two of his published books.  Specifically, Dr. Theodosakis published “The Arthritis Cure” and “Maximizing the Arthritis Cure” regarding the use of dietary supplements to treat arthritis patients.  Dr. Theodosakis alleged that his books have a distinctive trade dress, or cover layout, design, color and typeface, and those products that the defendants sold under the ARTHx trademarks infringed the books’ trade dress and constituted unfair competition and false designation of origin.  Additionally, Dr. Theodosakis alleged that the defendants made false endorsements of the products by referencing his books on the product packaging and that the use of his name, books and trade dress invaded his right to publicity.  The Company sold the ARTHx trademarks, goodwill and inventory to a third party, Contract Pharmacal Corporation, in March 2003.  On January 12, 2005, the court granted the Company’s motion for summary judgment and dismissed all

 

29



 

claims against Pecos and Medtech.  The plaintiff has filed an appeal in the U.S. Court of Appeals which is pending.

 

On January 3, 2005, the Company was served with process by its former lead counsel in the Theodosakis litigation seeking $679 plus interest.  The case was filed in the Supreme Court of New York and is styled as Dickstein Shapiro et al v. Medtech Products, Inc.  In February 2005, the plaintiffs filed an amended complaint naming the Pecos Pharmaceutical Company as defendant.  The Company has answered and filed a counterclaim against Dickstein and also filed a third party complaint against the Lexington Insurance Company.  The Company believes that if there is any obligation to the Dickstein firm relating to this matter, it is an obligation of Lexington and not the Company.

 

On May 9, 2005, the Company was served with a complaint in a class action lawsuit filed in Essex County, Massachusetts, styled as Dawn Thompson v. Wyeth, Inc. relating to the Company’s Little Remedies pediatric cough products.  The Company is one of several corporate defendants, all of whom market over-the-counter cough syrup products for pediatric use.  The complaint alleges that the ingredient dextromethorphan is no more effective than a placebo.  There is no allegation of physical injury caused by the product or the ingredient.  In June 2005, the Company was served in a second class action complaint involving dextromethorphan.  The second case, styled Tina Yescavage v. Wyeth was filed in Lee County Florida and similarly involves multiple corporate defendants.  The Company believes that both of the dextromethorphan cases are without merit and is activ